Evercore ISI resumed coverage of Waters (WAT) with an In Line rating and $360 price target. Shares have dipped by 13% post the Becton Dickinson (BDX) Life Sci transaction due to mixed results and cautious guidance, says the analyst, who notes that debate centers around management’s confidence in deal merits versus short-term concerns.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT:
- Maintaining Hold on Waters as BD Life Sciences Weakness and Reduced Premium Valuation Temper Near‑Term Upside
- Waters price target lowered to $350 from $410 at BofA
- Waters reinstated with an Overweight at Barclays
- Waters resumed with a Buy at Citi
- Waters Corp Earnings Call: Growth, Risks and Synergies